Journal ArticleDOI
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Reads0
Chats0
About:
This article is published in Yearbook of Oncology.The article was published on 2010-01-01. It has received 850 citations till now. The article focuses on the topics: Dasatinib & Imatinib.read more
Citations
More filters
Journal ArticleDOI
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
TL;DR: The current evidence regarding the cardiovascular safety profiles of BCR-ABL TKIs is presented and management strategies for cardiovascular surveillance and risk factor modification during treatment with these agents are proposed.
Journal ArticleDOI
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
Elias Jabbour,Jorge E. Cortes,Aziz Nazha,Susan O'Brien,Alfonso Quintás-Cardama,Sherry Pierce,Guillermo Garcia-Manero,Hagop M. Kantarjian +7 more
TL;DR: There was no difference in the major molecular response, TFS, EFS, and OS rates between patients with low and high EUTOS score, overall and within specific therapies.
Journal ArticleDOI
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
Timothy P. Hughes,Giuseppe Saglio,Alfonso Quintás-Cardama,Michael J. Mauro,Dong-Kee Kim,Jeffrey H. Lipton,M. B. Bradley-Garelik,Jon A. Ukropec,Andreas Hochhaus +8 more
TL;DR: Retrospective analyses were conducted to characterize mutation development in patients with newly diagnosed CML-CP treated with dasatinib or imatinib in DASISION (DasatinIB versus Imatinib Study in Treatment-Naive C ML-CP), with 3-year minimum follow-up.
Journal ArticleDOI
Tyrosine kinase inhibitors in acute and chronic leukemias
TL;DR: Ponatinib, a pan BCR-ABL TKI, is very hopeful with its ability to overcome T315I mutations in resistant CML and Ph + ALL patients, and is recommended based on the side-effect profile, drug interactions, patient comorbidities, and mutational status.
Journal ArticleDOI
Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy
TL;DR: Second-generation TKIs have the potential to replace imatinib as the standard of care for patients with early CML-CP and future CML therapy might include earlier use of these agents to help more patients achieve complete molecular response and may be a path to a CML cure.
References
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.